secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000917520-24-000059
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent
--------------------------------------------------------------------------------

- Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.
- Adjusted EPS $0.55 vs $0.74 prior year; adjusted EBITDA $71.8M (19.5% rev) vs $92.3M (24.2%).
- Acclarent acquisition closed April 1; FY2024 revenue guidance raised to $1.672-1.687B, adj. EPS guidance $3.01-3.11.
- Tissue Technologies revenue fell 15.3% driven by Boston recall; removing SurgiMend/PriMatrix relaunch from guidance due to audit findings.
- Codman Specialty Surgical grew 3.3% reported (4.4% organic); Neurosurgery up 6.3% organically, Instruments down 2.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/0000917520-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000059/iart-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000917520-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer